Merlin Biotech develops novel therapeutics using a clinically proven mRNA platform that encodes therapeutic proteins. Its lead candidate, MER-101, delivers mRNA for the USP6 protein to activate multiple immunostimulatory pathways, targeting adult solid tumors and the rare childhood cancer Ewing sarcoma. The company plans to monetize through partnerships, licensing agreements, and eventual product sales of its mRNA‑based drugs.
Funding
Funding not disclosed
Founders
Product
Problem
Many solid tumors evade detection by the body's immune system, limiting the effectiveness of traditional cancer treatments. Current therapeutic options for Ewing sarcoma, a rare childhood cancer, are also limited.
Solution
Merlin Biotech is developing mRNA-based therapeutics designed to enhance the immune system's ability to recognize and attack cancer cells. Their lead program, MER-101, utilizes a proprietary mRNA sequence encoding the USP6 protein. This protein activates multiple immunostimulatory pathways, effectively "uncloaking" cancer cells and making them more visible to the immune system. Merlin Biotech is initially focusing on adult solid tumors and Ewing sarcoma.
Target Audience
The primary target audience includes patients with adult solid tumors and children affected by Ewing sarcoma, as well as the oncologists and healthcare providers who treat them.
Features
- Proprietary mRNA platform for targeted delivery of therapeutic proteins
- MER-101: mRNA encoding the USP6 protein to stimulate multiple immune pathways
- Designed to enhance the immune system's ability to detect and target cancer cells
- Potential application across a range of solid tumors and rare cancers